Akkermansia muciniphila probiotic for obesity in children and teenagers
Tests a gut probiotic, Akkermansia muciniphila, in children and teenagers with obesity.
Plain-language title generated from the registry record
Registry title: AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents
Key facts
- Where
- Changsha, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 7 and 18 years old?
Source: NCT07593170, who can take part
Where in China
- Xiangya School of Public HealthChangsha, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Central South University
- Trial code
- NCT07593170
- Record updated
- 3 June 2026
- Original description
The problem of obesity among children and adolescents is becoming increasingly serious and may affect their health in adulthood. Researches have found that a type of probiotic in the intestinal tract - "Akkermansia muciniphila" (referred to as AKK), may help regulate metabolism and weight. Although it has shown effects in adults, its safety and efficacy in children and adolescents still need further verification.Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Study of Akkermansia Muciniphila AKK PROBIO in Improving Obesity and Metabolic Abnormalities in Children and Adolescents Aged 7-18 Years
The problem of obesity among children and adolescents is becoming increasingly serious and may affect their health in adulthood. Researches have found that a type of probiotic in the intestinal tract - "Akkermansia muciniphila" (referred to as AKK), may help regulate metabolism and weight. Although it has shown effects in adults, its safety and efficacy in children and adolescents still need further verification.
This study aims to evaluate the effects of supplementing Akkermansia Muciniphila AKK PROBIO on weight, metabolic health and intestinal flora of obese children and adolescents aged 7 to 18.
Inclusion: Age range: 7 years old to 18 years old (inclusive of boundary values), gender not restricted; Primary obesity: According to the WS/T 586-2018 standard issued by the National Health Commission of China, or the internationally recognized CDC/WHO standard, diagnosed as obesity (if BMI ≥ the 95th percentile of children of the same age and gender); The subjects and their legal guardians understand the research content, voluntarily participate and sign the written informed consent form (for guardians), and the informed consent form (for children aged 8 years and above); Able to comply with the research protocol, complete all visits and sample collection.
Exclusion: Have used antibiotics, probiotics, prebiotics or synbiotic products within 3 months prior to screening; Have a history of systemic use of glucocorticoids or other drugs that may affect weight and metabolism (such as metformin, systemic glucocorticoids, diuretics, etc.) within 1 month prior to screening; Have a definite endocrine disorder causing obesity (such as Cushing's syndrome, hypothyroidism), a genetic syndrome (such as Prader-Willi syndrome), or other known organic diseases; Have a severe primary disease of the liver, kidney, cardiovascular system, respiratory system or hematopoietic system, etc; Subjects are allergic to any component of the study product (AKK probiotic capsules or placebo); Have a history of severe gastrointestinal diseases, such as inflammatory bowel disease (IBD); Other conditions as determined by the researcher to be unsuitable for participation in this study; Subjects are participating in other clinical trials.